Immune-related adverse events following checkpoint inhibitor treatment in head and neck cancers: A comprehensive review
Head and neck cancers are a heterogeneous group of highly aggressive tumors and collectively represent the sixth most common cancer worldwide. Most head and neck cancers are squamous cell carcinomas (HNSCCs). Immunotherapy agents, namely anti-PD-1/PD-L1 and CTLA-4 inhibitors, are the cornerstone of...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-06-01
|
| Series: | Oral Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772906023000262 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|